Logo
x

Search

Subscribe Now

regeneron

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)

  • February 18, 2025
Regeneron Reports US FDA’s Acceptance of Resubmitted BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)

Regeneron Reports US FDA’s Acceptance of Resubmitted BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)

  • February 12, 2025
Regeneron Reveals Data from Extended P-III (PULSAR) Trial of Eylea HD for Wet Age-related Macular Degeneration

Regeneron Reveals Data from Extended P-III (PULSAR) Trial of Eylea HD for Wet Age-related Macular Degeneration

  • February 10, 2025
Regeneron Reports Interim Data from P-III (C-POST) Trial of Libtayo Adjuvant to Treat High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Regeneron Reports Interim Data from P-III (C-POST) Trial of Libtayo Adjuvant to Treat High-Risk Cutaneous Squamous Cell Carcinoma...

  • January 15, 2025
Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

  • December 20, 2024
Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein Occlusion

Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein O...

  • December 18, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.